Perspective

FDA approves Alcon’s AcrySof IQ PanOptix trifocal IOL

The AcrySof IQ PanOptix trifocal IOL, the first trifocal lens for cataract surgery patients in the United States, has been approved by the FDA, Alcon announced in a press release.

PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery, the release said. In a pivotal clinical study at 12 U.S. sites, more than 99% of PanOptix patients said they would choose the lens again, demonstrating high patient satisfaction.

“We are proud to bring this new class of IOLs to the largest eye care market in the world,” David J. Endicott, CEO of Alcon, said in the release. “We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.”

The company plans to begin training ophthalmologists in the U.S. and making the PanOptix and PanOptix toric IOLs available throughout the rest of the year and into early 2020. It will also launch a dedicated PanOptix website and multimedia awareness campaign, the release said.

The AcrySof IQ PanOptix trifocal IOL, the first trifocal lens for cataract surgery patients in the United States, has been approved by the FDA, Alcon announced in a press release.

PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery, the release said. In a pivotal clinical study at 12 U.S. sites, more than 99% of PanOptix patients said they would choose the lens again, demonstrating high patient satisfaction.

“We are proud to bring this new class of IOLs to the largest eye care market in the world,” David J. Endicott, CEO of Alcon, said in the release. “We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.”

The company plans to begin training ophthalmologists in the U.S. and making the PanOptix and PanOptix toric IOLs available throughout the rest of the year and into early 2020. It will also launch a dedicated PanOptix website and multimedia awareness campaign, the release said.

    Perspective
    John A. Hovanesian

    John A. Hovanesian

    Internationally, the adoption of trifocal lens implants like the Alcon PanOptix has eclipsed traditional multifocals because trifocals deliver functional vision for distance, intermediate and near without requiring monovision or mixing and matching different IOLs. Binocular summation is a strong visual reward for patients and one that we compromise to some degree when each eye is focused differently.

    This first trifocal lens will have its limitations, like every other new offering on the market, but if the sentiment of our European colleagues, who have used this lens for several years, is any predictor of the future, they will be very well accepted and implanted frequently.

    • John A. Hovanesian, MD, FACS

    Disclosures: Hovanesian reports he is a consultant to Alcon, Bausch + Lomb, Johnson & Johnson Vision and Zeiss.